Options Trading for Adaptive Biotechnologies (ADPT) in the First Week of February 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: NASDAQ.COM
Put Contract Overview: The $15.00 put contract for ADPT has a bid of 10 cents, allowing investors to buy shares at $15.00 while collecting a premium, effectively lowering the cost basis to $14.90. This represents a 10% discount to the current price of $16.66, with a 68% chance of the contract expiring worthless.
Call Contract Overview: The $17.50 call contract has a bid of 30 cents, enabling investors to sell shares at that price after purchasing at $16.66. This could yield a total return of 6.84% if exercised, but there's a 45% chance it may expire worthless, allowing investors to keep both the shares and the premium.
YieldBoost Calculation: If the put contract expires worthless, it would yield a 0.67% return on cash commitment (3.86% annualized), while the covered call could provide a 1.80% boost (10.43% annualized) if it also expires worthless.
Volatility Insights: The implied volatility for the put contract is 130%, while for the call contract it is 106%. The actual trailing twelve-month volatility is calculated at 74%, indicating potential fluctuations in stock price.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ADPT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ADPT
Wall Street analysts forecast ADPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADPT is 20.25 USD with a low forecast of 20.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 18.500
Low
20.00
Averages
20.25
High
21.00
Current: 18.500
Low
20.00
Averages
20.25
High
21.00
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Adaptive Biotechnologies Reports 55% Revenue Growth to $277 Million for FY 2025
- Significant Revenue Growth: Adaptive Biotechnologies reported preliminary unaudited revenue of approximately $277 million for FY 2025, reflecting a robust 55% year-over-year increase, which is expected to bolster market confidence in the company's growth trajectory.
- Strong Q4 Performance: The company achieved approximately $72 million in revenue for Q4 2025, a 51% increase compared to the same quarter in 2024, with minimal residual disease (MRD) revenue reaching $62 million, indicating ongoing expansion in precision medicine.
- Testing Volume Surge: clonoSEQ testing volume surged by 43% in Q4 2025 to approximately 30,000 tests, with a total of about 105,600 tests delivered for the year, marking a 39% increase from 2024, showcasing rising market demand for this testing service.
- Robust Cash Reserves: As of December 31, 2025, the company reported approximately $227 million in cash, cash equivalents, and marketable securities, providing substantial flexibility for future investments and research and development initiatives.
Continue Reading
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
Continue Reading